By proceeding, you agree to our Terms of Use and Privacy Policy.
Jeffrey Martin is actively involved in groundbreaking research with a focus on XPO1, a therapeutic target with implications in both oncology and amyotrophic lateral sclerosis (ALS). His work centers on the development and application of clickable probes, coupled with a mass spectrometry-based chemoproteomic workflow designed to measure in vivo XPO1 target occupancy. In his presentations, Jeffrey will elucidate the innovative tools and methodologies employed, shedding light on their effectiveness in various biological matrices and in vivo models. This research holds significant promise for advancing our understanding of XPO1-related mechanisms and potentially unlocking new avenues for therapeutic interventions in the realms of cancer and ALS.
Talks About #MassSpectrometry #Microfluidics #Biochemistry #AssayDevelopment
Preferred Locations #NorthAmerica